New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 10, 2014
10:02 EDTRHHBY, MKGAYRoche unit, Merck KGaA to develop companion test for cancer treatment
Ventana Medical Systems, a member of the Roche Group (RHHBY), announced it has entered into an agreement with Merck KGaA (MKGAY), which operates as EMD Serono in the United States and Canada, to collaborate with Merck KGaA's biopharmaceutical division on the development and commercialization of a companion diagnostic for an undisclosed target using Ventana's proprietary diagnostic assays.
News For RHHBY;MKGAY From The Last 14 Days
Check below for free stories on RHHBY;MKGAY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 20, 2014
15:43 EDTRHHBYInterMune reports MOU in connection with consolidated Delaware action
Subscribe for More Information
September 18, 2014
06:21 EDTMKGAYMerck KGaA names Stefan Oschmann as deputy CEO
Subscribe for More Information
September 17, 2014
11:00 EDTRHHBYRoche CEO rules out megadeals, focused on bolt-on acquisitions, WSJ says
Roche CEO Severin Schwan said the company won't change its acquisition strategy following the recent deals made or abandoned in the pharmaceutical sector, reports the Wall Street Journal. In an interview with WSJ, Shwan said, "We have been very consistent in our approach to M&A." Regarding transformational deal-making, he said, "We have no intention to do that, whatever happens in the industry." Reference Link
07:43 EDTRHHBYBofA/Merrill to hold a conference
Subscribe for More Information
September 16, 2014
07:31 EDTRHHBYEuropean Association for Study of Diabetes to hold annual meeting
50th Annual Meeting of EASD to be held in Vienna, Austria on September 15-19.
September 12, 2014
09:14 EDTMKGAYOn The Fly: Pre-market Movers
Subscribe for More Information
08:39 EDTMKGAYOncothyreon says Merck KGaA discontinues development of tecemotide in NSCLC
Oncothyreon (ONTY) disclosed earlier in a regulatory filing that Merck KGaA (MKGAY), which has world-wide rights for the development and commercialization of tecemotide under a license agreement with Oncothyreon, announced that its biopharmaceutical division will discontinue the clinical development program of the investigational MUC1 antigen-specific cancer immunotherapy as a monotherapy in Stage III non-small cell lung cancer, or NSCLC. The decision to discontinue the current clinical program in NSCLC, which includes the Phase III START2 and INSPIRE studies, follows recent results from a planned analysis of EMR 63325-009, a randomized, double-blind, placebo-controlled Phase I/II study in Japanese patients. Merck Serono has made the decision to discontinue all other Merck Serono-sponsored clinical trials with tecemotide in NSCLC worldwide. Those patients on active treatment with tecemotide can undergo an individual assessment by their treating physician and apply to receive further treatment outside of the studies. Merck Serono will continue to supply tecemotide for ongoing investigator-sponsored trials in other indications in accordance with their agreements with the sponsors of these studies. Shares of Oncothyreon are down 12% in pre-market trading following the news from its partner.
September 10, 2014
13:04 EDTRHHBYRoche unit receives orphan status for lung cancer mutation drug
Subscribe for More Information
September 8, 2014
07:15 EDTRHHBYIBC Life Sciences to hold a conference
10th Annual Cell Line Development & Engineering Conference to be held in Berkeley, California on September 8-10.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use